Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Other Non Operating Income: 2014-2025

Historic Other Non Operating Income for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $4.1 million.

  • Theravance Biopharma's Other Non Operating Income rose 192.51% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 27.73%. This contributed to the annual value of $4.9 million for FY2024, which is 46.46% down from last year.
  • Per Theravance Biopharma's latest filing, its Other Non Operating Income stood at $4.1 million for Q3 2025, which was up 184.08% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Other Non Operating Income ranged from a high of $4.1 million in Q3 2025 and a low of -$3.0 million during Q3 2022.
  • In the last 3 years, Theravance Biopharma's Other Non Operating Income had a median value of $1.5 million in 2025 and averaged $1.9 million.
  • Data for Theravance Biopharma's Other Non Operating Income shows a peak YoY increase of 1,001.18% (in 2022) and a maximum YoY decrease of 1,727.71% (in 2022) over the last 5 years.
  • Theravance Biopharma's Other Non Operating Income (Quarterly) stood at $338,000 in 2021, then soared by 1,001.18% to $3.7 million in 2022, then tumbled by 50.38% to $1.8 million in 2023, then crashed by 51.06% to $904,000 in 2024, then soared by 192.51% to $4.1 million in 2025.
  • Its Other Non Operating Income was $4.1 million in Q3 2025, compared to $1.5 million in Q2 2025 and $939,000 in Q1 2025.